Conferenze Formative - Joseph Gligorov

Programma

• 24 gennaio
  Optimizing the designs of early clinical trials in oncology
  Christina Yap, UK,
  Professor of Clinical Trials Biostatistics, The Institute of Cancer Research, UK
   
• 14 febbraio 
  Senolytic immune cells therapies for prostate cancer
  Andrea Alimonti, CH,
  Head of molecolar oncology at the Institute of Oncology Research (IOR-CH),
  Full Professor of Oncology USI, ETH, CH
  Full professor of Pharmacology UNiPD, IT
   
• 27 marzo 
  The changing landscape of relapsed and refractory diffuse large B-cell lymphoma
  Andrew Davies, UK
  Professor of Haematological Oncology and Honorary Consultant, University of Southampton, UK
  Chair UK National Lymphoma Research Group
  Director Southampton Experimental Cancer Medicines Centre
   
• 17 aprile 
  Advances in DDR targeting: what can we expect in the next years
  Timothy A Yap, USA
  Professor, Department of Investigational Cancer Therapeutics (Phase I Program)
  Vice President, Head of Clinical Development, Therapeutics Discovery Division
  Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
  The University of Texas MD Anderson Cancer Center
   
• 15 maggio 
  Systematic reviews in a nutshell
  Giorgio Treglia, CH
  Medical education and Research Area and Imaging Institute of Southern Switzerland, EOC, Bellinzona
  Professor, Faculty of Biomedical sciences, USI, Lugano
  Faculty of Biology and Medicine, UNIL, Lausanne
   
• 19 giugno 
  Management of antibody-drug conjugates toxicities
  Joseph Gligorov, FR
  Professor of Medical Oncology Sorbonne Université
  Medical Director of DMU ORPHé AP-HP Sorbonne Université
   
• 18 settembre 
  ctDNA and MRD in solid tumors: current state and future directions
  Umberto Malapelle, IT
  Chair of Predictive Molecular Pathology Laboratory, Department of Public Health
  University Federico II of Naples, Italy
   
• 23 ottobre 
  New KRAS inhibitors beyond G12C
  Fabrice Barlesi, FR
  General Director of Gustave Roussy
  Professor of Medicine at the Paris Saclay University, France
   
• 20 novembre 
  Update on cellular therapies for solid tumours
  Andrew Furness, UK
  Consultant Medical Oncologist, Solid Tumour Cellular Therapy Lead, The Royal Marsden NHS Foundation Trust
  Team Leader and Clinical Lead, Centre for Translational Immunotherapy, The Institute of Cancer Research